FDA panel casts doubt on Grail's multi-cancer screening accuracy
An FDA advisory committee and agency officials expressed concerns about the performance of Grail's next-generation sequencing test for early cancer detection in adults over 50. The questions raised during the Wednesday meeting centered on the test's effectiveness. The outcome could influence the test's regulatory approval prospects.
The advisory committee's skepticism centers on whether the blood-based test reliably detects multiple cancer types in asymptomatic adults aged 50 and older. Agency officials reportedly questioned the test's performance metrics, particularly its accuracy and potential for false results. The test uses next-generation sequencing to identify tumor-derived signals in the bloodstream, a promising but technically challenging approach.
This meeting represents a critical juncture for Grail's regulatory pathway. While multi-cancer early detection tests hold significant promise for improving survival rates, regulators must weigh potential benefits against the risks of missed cancers or unnecessary follow-up procedures. The committee's concerns could shape future requirements for similar diagnostic technologies.
This decision could affect millions of older adults considering routine cancer screening, as well as insurers determining coverage. If approval is delayed or denied, patients may lose access to a potentially valuable early-detection tool, while developers of similar tests may face stricter standards. Conversely, rigorous scrutiny could prevent widespread adoption of a test with uncertain accuracy, sparing patients from false alarms or false reassurance. The outcome may also influence investment in the multi-cancer screening field.